Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic hepatiti

[Guest guest]

Gut. 2006 Feb 4; [Epub ahead of print]

Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic

hepatitis B patients treated with ADV.

Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS,

Kim SO, Byun KS, Lee CH.

Korea University Medical College Guro Hospital, Korea, Republic of.

BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against

both the wild-type and lamivudine (LMV)-resistant HBV. The cumulative

incidences of ADV resistant mutations in the nucleoside/-tide treatment na?e

chronic hepatitis B patients (CHB) at weeks 48, 96, 144 were 0, 0.8-3% and

~5.9%, respectively. AIMS: The aim of this study was to characterize the

genotypic and phenotypic mutation profiles to ADV in 67 LMV-resistant CHB

patients who were treated with ADV. METHODS: The serum HBV DNA was

quantified by real time PCR. The ADV mutant was detected by using

matrix-assisted laser desorption/ionization time of flight mass

spectrometry-based genotyping assays, termed Restriction Fragment Mass

Polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11

amino acid substitutions developed in the rt domain of the HBV polymerase in

9 patients. The cumulative incidence of genotypic ADV resistance at months

12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T and rtA181T

mutations were detected in 5, 4 and 2 of the 67 patients at treatment months

12~17, 3~19 and 7~20, respectively. Serial quantification of the serum HBV

DNA revealed that two patients with the rtA181V mutation that were with or

without the rtN236T mutation and one patient with the rtA181T mutation

displayed the HBV DNA rebound. CONCLUSION: The emergence of the ADV mutation

in LMV resistant patients who are treated with ADV appeared to present

earlier and more frequent than was reported in the previous studies on

nucleoside/-tide treatment na?e patients.

PMID: 16461777

_________________________________________________________________

On the road to retirement? Check out MSN Life Events for advice on how to

get there! http://lifeevents.msn.com/category.aspx?cid=Retirement

[Guest guest]

Gut. 2006 Feb 4; [Epub ahead of print]

Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic

hepatitis B patients treated with ADV.

Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS,

Kim SO, Byun KS, Lee CH.

Korea University Medical College Guro Hospital, Korea, Republic of.

BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against

both the wild-type and lamivudine (LMV)-resistant HBV. The cumulative

incidences of ADV resistant mutations in the nucleoside/-tide treatment na?e

chronic hepatitis B patients (CHB) at weeks 48, 96, 144 were 0, 0.8-3% and

~5.9%, respectively. AIMS: The aim of this study was to characterize the

genotypic and phenotypic mutation profiles to ADV in 67 LMV-resistant CHB

patients who were treated with ADV. METHODS: The serum HBV DNA was

quantified by real time PCR. The ADV mutant was detected by using

matrix-assisted laser desorption/ionization time of flight mass

spectrometry-based genotyping assays, termed Restriction Fragment Mass

Polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11

amino acid substitutions developed in the rt domain of the HBV polymerase in

9 patients. The cumulative incidence of genotypic ADV resistance at months

12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T and rtA181T

mutations were detected in 5, 4 and 2 of the 67 patients at treatment months

12~17, 3~19 and 7~20, respectively. Serial quantification of the serum HBV

DNA revealed that two patients with the rtA181V mutation that were with or

without the rtN236T mutation and one patient with the rtA181T mutation

displayed the HBV DNA rebound. CONCLUSION: The emergence of the ADV mutation

in LMV resistant patients who are treated with ADV appeared to present

earlier and more frequent than was reported in the previous studies on

nucleoside/-tide treatment na?e patients.

PMID: 16461777

_________________________________________________________________

On the road to retirement? Check out MSN Life Events for advice on how to

get there! http://lifeevents.msn.com/category.aspx?cid=Retirement

[Guest guest]

Gut. 2006 Feb 4; [Epub ahead of print]

Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic

hepatitis B patients treated with ADV.

Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS,

Kim SO, Byun KS, Lee CH.

Korea University Medical College Guro Hospital, Korea, Republic of.

BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against

both the wild-type and lamivudine (LMV)-resistant HBV. The cumulative

incidences of ADV resistant mutations in the nucleoside/-tide treatment na?e

chronic hepatitis B patients (CHB) at weeks 48, 96, 144 were 0, 0.8-3% and

~5.9%, respectively. AIMS: The aim of this study was to characterize the

genotypic and phenotypic mutation profiles to ADV in 67 LMV-resistant CHB

patients who were treated with ADV. METHODS: The serum HBV DNA was

quantified by real time PCR. The ADV mutant was detected by using

matrix-assisted laser desorption/ionization time of flight mass

spectrometry-based genotyping assays, termed Restriction Fragment Mass

Polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11

amino acid substitutions developed in the rt domain of the HBV polymerase in

9 patients. The cumulative incidence of genotypic ADV resistance at months

12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T and rtA181T

mutations were detected in 5, 4 and 2 of the 67 patients at treatment months

12~17, 3~19 and 7~20, respectively. Serial quantification of the serum HBV

DNA revealed that two patients with the rtA181V mutation that were with or

without the rtN236T mutation and one patient with the rtA181T mutation

displayed the HBV DNA rebound. CONCLUSION: The emergence of the ADV mutation

in LMV resistant patients who are treated with ADV appeared to present

earlier and more frequent than was reported in the previous studies on

nucleoside/-tide treatment na?e patients.

PMID: 16461777

_________________________________________________________________

On the road to retirement? Check out MSN Life Events for advice on how to

get there! http://lifeevents.msn.com/category.aspx?cid=Retirement

[Guest guest]

Gut. 2006 Feb 4; [Epub ahead of print]

Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic

hepatitis B patients treated with ADV.

Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS,

Kim SO, Byun KS, Lee CH.

Korea University Medical College Guro Hospital, Korea, Republic of.

BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against

both the wild-type and lamivudine (LMV)-resistant HBV. The cumulative

incidences of ADV resistant mutations in the nucleoside/-tide treatment na?e

chronic hepatitis B patients (CHB) at weeks 48, 96, 144 were 0, 0.8-3% and

~5.9%, respectively. AIMS: The aim of this study was to characterize the

genotypic and phenotypic mutation profiles to ADV in 67 LMV-resistant CHB

patients who were treated with ADV. METHODS: The serum HBV DNA was

quantified by real time PCR. The ADV mutant was detected by using

matrix-assisted laser desorption/ionization time of flight mass

spectrometry-based genotyping assays, termed Restriction Fragment Mass

Polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11

amino acid substitutions developed in the rt domain of the HBV polymerase in

9 patients. The cumulative incidence of genotypic ADV resistance at months

12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T and rtA181T

mutations were detected in 5, 4 and 2 of the 67 patients at treatment months

12~17, 3~19 and 7~20, respectively. Serial quantification of the serum HBV

DNA revealed that two patients with the rtA181V mutation that were with or

without the rtN236T mutation and one patient with the rtA181T mutation

displayed the HBV DNA rebound. CONCLUSION: The emergence of the ADV mutation

in LMV resistant patients who are treated with ADV appeared to present

earlier and more frequent than was reported in the previous studies on

nucleoside/-tide treatment na?e patients.

PMID: 16461777

_________________________________________________________________

On the road to retirement? Check out MSN Life Events for advice on how to

get there! http://lifeevents.msn.com/category.aspx?cid=Retirement